After selling his pharmaceutical company, Ovation Pharmaceuticals, in 2009, Marathon Pharmaceuticals CEO Jeff Aronin sat down with the Chicago Tribune to talk exits, startups and orphan drugs.
Entrepreneur Jeff Aronin sold his pharmaceutical company for $900 million in 2009. In 2010, he decided to do it all over again.
Aronin won big by focusing on the small; his Ovation Pharmaceuticals, bought six years ago by Denmark-based Lundbeck, focused on developing niche drugs for small patient populations.
Northbrook-based Marathon Pharmaceuticals, which Aronin founded in 2010, also focuses on niche drugs for the treatment of rare neurological and movement disorders. The company hopes to win FDA approval for a drug for Duchenne muscular dystrophy in 2016.